Pulsenmore

Company Overview

Snapshot

Founded in October 2014 by Elazar Sonnenschein, Pulsenmore operates with 51–200 employees. The company has raised a total of $110.8M across 5 funding rounds from 6 investors. In January 2026, Pulsenmore announced its shares would commence trading on Nasdaq, expanding its FDA-authorized home prenatal ultrasound devices in the U.S.

Business overview

Pulsenmore develops a universally accessible home ultrasound device for remote care, enabling patients to self-scan using a handheld ultrasound cradle connected to their smartphone. The technology facilitates remote clinical assessment by healthcare providers, particularly for at-home prenatal ultrasound to monitor fetal well-being. The company's solutions aim to enhance care availability, improve resource management, and increase patient satisfaction within the Health Tech & Life Sciences sector, specifically targeting medical devices, digital healthcare, and patient remote monitoring.

Strategic signal

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound, marking a significant regulatory milestone for the company. This authorization is a strong signal to investors, validating the technology's safety and efficacy for the U.S. market and positioning Pulsenmore as a pioneer in remote prenatal care. This development is expected to drive substantial growth and market penetration in a key global healthcare market.

Company Intelligence Q&A

What significant regulatory approval did Pulsenmore receive in the U.S.?

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound device, marking a new era for prenatal care in the U.S.

What was a key strategic development for Pulsenmore in January 2026?

In January 2026, Pulsenmore announced its shares would commence trading on Nasdaq, coinciding with the expansion of its FDA-authorized home prenatal ultrasound devices in the U.S.

When did Pulsenmore expand its partnership with Clalit Health Services?

In October 2024, Pulsenmore expanded its partnership with Clalit Health Services to deliver 25,000 home ultrasound devices for remote prenatal care.

What new commercial engagement did Pulsenmore announce in February 2026?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center, building momentum in the U.S. market after FDA clearance.

What leadership appointment did Pulsenmore make in June 2024?

In June 2024, Pulsenmore appointed Len Farris as.